After several years of constrained capital and cautious investor sentiment, funding activity is returning to the biotech sector. In the fourth quarter of 2025, publicly traded developers raised more than $13 billion, the highest quarterly total since 2021. While activity remains selective, this shift reflects improving market conditions and renewed engagement with higher-risk sectors as interest rates ease.
For biotech companies that endured the downturn, the window to secure financing or a follow-on raise is opening. Capital is moving again, but at a faster pace and with heightened expectations. As competition for investor attention intensifies, the next opportunity will require quick, diligent, and coordinated execution.
Understanding the Risk Environment and Investor Priorities
Scientific uncertainty is inherent to biotech, and investors have largely priced this variable into their analysis. While investor appetite may be shifting to embrace scientific risk, there remains little tolerance for other types of risk, whether they are financial, operational, or timing-based.
As funding activity resumes, organizations must account for three types of risk:
Industry risk encompasses the scientific and clinical uncertainty native to drug development. While investors understand this variable and incorporate it into valuations, companies must demonstrate a clear understanding of development hurdles and articulate a strategic plan to address them.
Timing risk reflects organizational readiness and sophistication. Missed regulatory filings, audit readiness gaps, or SEC deadlines can mean forfeiting the opportunity entirely. Funding windows can open and close with startling speed, and investors evaluate pace as a proxy for organizational maturity.
Execution risk is where scrutiny becomes most intense, and where many companies falter. Investors assess whether leadership can coordinate their advisors effectively, respond to due diligence, and maintain financial clarity under pressure. Gaps in communication, ambiguous ownership of deliverables, or a weak financial understanding will quickly diminish confidence.
While industry risk cannot be eliminated, timing and execution risks are controllable with the right preparation and alignment.
Common Audit Pitfalls that Derail Fundraising
Investors generally look for the same attributes: clean financial records, strong governance structures, and operational discipline. Most biotech companies that reach the capital markets stage understand this intellectually, yet many stumble in execution. The difference lies in understanding investor expectations and executing the audit with coordinated teamwork.
1. Advisor Misalignment
Many companies view their audit team, legal counsel and bankers as independent workstreams. When coordination is unclear, rework and delays cascade through the entire process. The whole team must work toward the same timeline and share clear milestones, rather than operating in silos.
2. Weak Financial Command
Equity structures in biotech are complex. CFOs must understand cap table dynamics at a granular level and be able to clearly explain how investment scenarios impact product or treatment milestones, as well as their impacts on existing investors. When the CFO cannot confidently explain equity structure and its impact on the financials, investor confidence diminishes.
3. Lack of Cost Certainty and Timeline Structure
Leadership must clearly understand all costs and their timing during a raise. Some fees, such as those required to maintain auditor independence, must be paid upfront, while others can be covered by transaction proceeds at closing. It is also critical to know your net proceeds after all costs are paid. This will shape decisions about how much to raise and what type of offering makes sense, such as common or preferred stock, with or without warrants, and related decisions.
Investors view strong cost discipline and transparent financial planning as core indicators of management’s sophistication and execution capability. Your choice of auditor and service providers is fundamental, as it can impact not just the process but also market perception and, ultimately, the outcome of the raise.
Advisors Who Move You Forward
Investors view advisors as an extension of management. The choice of an audit firm and capital markets advisors reflects your company’s capacity to meet regulatory standards, handle complexity and perform under pressure.
Experience matters in practical and measurable ways. Advisors skilled across the entire process — who have guided companies through IPOs, follow-on offerings, and institutional capital rounds — understand where processes slow down, what investors expect at each stage, and how to maintain momentum when timelines compress.
Grassi’s SEC & Capital Markets team works with biotech and growth-stage companies navigating these transactions. Our focus is on establishing financial clarity early, aligning advisors around shared milestones, and structuring reporting timelines to avoid unnecessary delays.
Preparing for the 2026 Window
Capital is becoming available, but selectively, and execution standards are high. Those considering a funding raise in 2026 should prepare now by prioritizing three things:
- Financial clarity, including cap table understanding and reporting readiness
- Clear decision authority and accountability across the management team
- Advisors with direct experience managing capital markets timelines
To discuss how to position your company for the next opportunity, contact Grassi’s SEC & Capital Markets team.
Frequently Asked Questions
Q: Why is auditor selection important during biotech fundraising?
A: Investors evaluate your audit team as a signal of management quality. A firm with biotech fundraising experience and proven coordination across legal, banking and audit functions demonstrates capability and helps you deliver with quality and pace.
Q: What are the common pitfalls that derail fundraising?
A: Lack of team coordination, weak financial command, and unclear timelines and costs. These emerge when expectations between stakeholders aren’t aligned or when advisors lack sector and capital markets expertise.
Q: What does the return of biotech funding mean for companies in 2026?
A: The funding environment is moving again, but capital is selective. Companies that capitalize combine strong execution with experienced advisors who understand biotech complexity and can navigate compressed timelines.
Q: How can biotech companies prepare for fundraising on a compressed timeline?
A: Ensure your CFO, audit firm, and bankers move in alignment from day one. Create financial clarity before the audit begins. Coordinate on timelines and costs upfront to avoid duplicative work and delays.
